N. Mylonakis

Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer

D. Skarlos, E. Samantas, P. Kosmidis et al. · Annals of Oncology · 1994 · 274 citations · Full text

Radiation Medicine, Health Sciences, Radiation Therapy +8

Gemcitabine and oxaliplatin (GEMOX) in patients withcisplatin-refractory germ cell tumors: a phase II study

D. Pectasides, Melina Pectasides, Dimitrios Farmakis et al. · Annals of Oncology · 2004 · 101 citations

Genitourinary Cancer, Medicine, Phase Ii Study +5

Phase II study of liposomal cisplatin (Lipoplatin™) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer

N. Mylonakis, A E Athanasiou, Nikolaos Ziras et al. · Lung Cancer · 2009 · 96 citations

Liposomal Cisplatin, Medicine, Pathology +7

Comparison of docetaxel and docetaxel–irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial

D. Pectasides, Melina Pectasides, Dimitrios Farmakis et al. · Annals of Oncology · 2005 · 85 citations · Full text

Medicine, Metronomic Therapy, Pharmacology +8

Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): A multicenter randomized trial

P. Kosmidis, N. Mylonakis, Dimosthenis Skarlos et al. · Annals of Oncology · 2000 · 74 citations · Full text

Medicine, Metronomic Therapy, Pharmacology +5